GO
Loading...

Medicine

More

  • Teva buying Auspex for $3.2 billion Monday, 30 Mar 2015 | 7:31 AM ET

    NEW YORK— Teva Pharmaceutical Industries Ltd. is buying Auspex Pharmaceuticals for about $3.2 billion in a move to strengthen its position on central nervous system condition treatments. Jerusalem- based Teva said Monday that it will pay $101 per share, marking a 47 percent premium to San Diego- based Auspex's closing stock price on Friday.

  • MINNEAPOLIS— An outbreak of a deadly bird flu strain spread to one of the top poultry producing counties of the nation's top turkey producing state of Minnesota, government officials confirmed on Saturday, raising fears that the that the highly contagious disease could seriously damage the industry. The highly pathogenic H5N2 strain of avian influenza has...

  • SINGAPORE/ SYDNEY, March 27- As investigators probe why a young German pilot deliberately crashed an Airbus A320 passenger jet into the French Alps on Tuesday, pilots and psychologists warn there is no foolproof way to prevent similar incidents in the future. Asian airlines including Cathay Pacific, Japan Airlines, Qantas Airways and Singapore Airlines said...

  • NEW YORK— Orexigen Therapeutics said Thursday that European Union regulators approved its weight loss drug for sale. Shares of Orexigen Therapeutics Inc. were up 18 cents, or 2.6 percent, to $7.10 in afternoon trading after rising to $7.47 earlier in the day. Orexigen's partner Takeda Pharmaceuticals handles marketing of Contrave and pays royalties to...

  • March 26- Conatus Pharmaceuticals Inc said its experimental lead drug was more effective than a placebo in a mid-stage study in patients with a form of fatty liver disease. Several drugmakers, including Gilead Sciences Inc, Intercept Pharmaceuticals Inc and France's Genfit SA, are in the race to develop treatments. Conatus estimates that about 2 million...

  • Conatus Pharma's liver drug succeeds in mid-stage study Thursday, 26 Mar 2015 | 7:02 AM ET

    March 26- Conatus Pharmaceuticals Inc said its experimental lead drug was more effective than a placebo in a mid-stage study in patients with a form of fatty liver disease. Several drugmakers, including Gilead Sciences Inc, Intercept Pharmaceuticals Inc and France's Genfit SA, are in the race to develop treatments. Conatus estimates that about 2 million...

  • A look at some key statistics on rare diseases in the US Wednesday, 25 Mar 2015 | 11:09 AM ET

    The global pharmaceutical industry is make huge investments in treatments for rare diseases, which once drew little interest from major drugmakers. A look at some key statistics on rare diseases:. —Percentage of rare diseases with an FDA- approved treatment: 5 percent.

  • FDA approves new drug for anthrax poisoning Wednesday, 25 Mar 2015 | 10:43 AM ET

    The Food and Drug Administration approved Anthrasil for use in combination with older antibiotics to treat inhalation anthrax, which can cause serious injury and death. The drug's development was funded by the U.S. government's Biomedical Advanced Research and Development Authority, which stockpiles vaccines, drugs and equipment for use during...

  • March 25- Emergent BioSolutions Inc said the U.S. Food and Drug Administration approved its treatment for inhaled anthrax, triggering a $7 million milestone payment from the Department of Health and Human Services. Emergent Bio developed the treatment, Anthrasil, as part of a $160 million contract it signed in 2005 with the Biomedical Advanced Research and...

  • JERUSALEM, March 25- Israeli biopharmaceutical company BioLineRX Ltd said on Wednesday an early stage trial for a drug that uses stem cells to treat leukaemia and other blood cancers met all safety and efficacy goals. Current stem cell treatments require four or five days of injections of material from a donor to get into the bloodstream, but BioLineRX said its...

  • March 25- Emergent BioSolutions Inc said the U.S. Food and Drug Administration approved its treatment for inhaled anthrax, triggering a $7 million milestone payment from the U.S. Department of Health and Human Services. Emergent Bio developed the treatment, Anthrasil, as part of a $160 million contract it signed in 2005 with the Biomedical Advanced Research...

  • FDA approves Emergent BioSolutions' anthrax treatment Wednesday, 25 Mar 2015 | 7:15 AM ET

    March 25- Emergent BioSolutions Inc said the U.S. Food and Drug Administration approved its treatment for inhaled anthrax, triggering a $7 million milestone payment from the U.S. Department of Health and Human Services.

  • EXCLUSIVE-DRUG THAT CAUSED "ELEPHANT MAN" SIDE EFFECT MAKES. LONDON, March 24- An experimental drug that caused appalling side effects in a clinical trial nine years ago is back in tests for rheumatoid arthritis and is showing promise when given at a fraction of the original dose. It is a remarkable turnaround from March 2006, when six healthy volunteers given the...

  • March 24- Merck& Co Inc said on Tuesday that it would stop a large study of its Keytruda melanoma treatment early because an independent monitoring committee determined the drug succeeded in its goal of prolonging survival in previously untreated patients at advanced stage of the disease. The medicine, a PD-1 inhibitor that works by taking the brakes off the...

  • CHICAGO, March 23- The U.S. government is developing a vaccine to protect poultry from new strains of avian flu that have recently killed birds from Arkansas to Washington state. In response to the cases, key overseas buyers have limited imports of U.S. poultry, and the world's biggest poultry producers, including Tyson Foods Inc and Sanderson Farms Inc, have...

  • UPDATE 1-FDA approves Abiomed's blood pump device Monday, 23 Mar 2015 | 6:16 PM ET

    March 23- The U.S. Food and Drug Administration said it approved Abiomed Inc's miniature blood pump system that maintains heart function and circulation during high-risk procedures. Angioplasty and stenting are procedures used to re-open arteries in the heart that are blocked due to coronary artery disease, a condition that is the leading cause of death in...

  • CHICAGO, March 23- The U.S. government is developing a vaccine to protect poultry from new strains of avian flu that have recently killed birds from Arkansas to Washington state. The world's biggest poultry producers, including Tyson Foods Inc and Sanderson Farms Inc, have increased biosecurity at farms to protect their flocks. The United States is developing...

  • FDA approves Abiomed's blood pump device Monday, 23 Mar 2015 | 5:51 PM ET

    March 23- The U.S. Food and Drug Administration said it approved Abiomed Inc's miniature blood pump system that maintains heart function and circulation during high-risk procedures. The device, Impella 2.5 System, can be used during angioplasty and stenting, the regulator said on Monday. Angioplasty and stenting are procedures used to re-open arteries in the...

  • March 23- The U.S. Food and Drug Administration said it would not recommend changes to the prescribing or use of Eli Lilly and Co's schizophrenia drug after a review of two deaths. The FDA said its investigation into the deaths was inconclusive. It carries a boxed warning, FDA's most serious type of warning, for post-injection delirium sedation or olanzapine...

  • March 23- The U.S. Food and Drug Administration said it would not recommend changes to the prescribing or use of Eli Lilly and Co's schizophrenia drug after a review of two deaths. Elevated levels of the drug, Zyprexa Relprevv, were found in the two patients who died three to four days after receiving the injection. The FDA said its investigation into the deaths was...